Lecigon

Entacapone / Levodopa / Carbidopa, the active ingredient in Lecigon, is a COMT inhibitor and DOPA decarboxylase inhibitor combination presented as a combination tablet for oral use. It is used to treat Parkinson's disease and to manage motor fluctuations in patients with Parkinson's disease.

GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigon, a COMT inhibitor and DOPA decarboxylase inhibitor combination, is used in the management of Parkinson’s disease and related motor fluctuations. - Parkinson's disease: improves motor symptoms by increasing central dopamine availability. - Motor fluctuations in Parkinson's disease: reduces “off” time and extends “on” periods. - Adjunct to levodopa therapy: enhances the effectiveness of levodopa in Parkinsonian patients.

Lecigon may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach and urge to vomit. - Dizziness: feeling light‑headed or unsteady. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, hepatic failure. - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Allergic reactions: rash, swelling, anaphylaxis.

Before prescribing Lecigon, clinicians should consider several safety precautions. - Monitor liver function: perform baseline tests and periodic assessments. - Assess cardiovascular status: watch for hypotension and arrhythmias. - Review psychiatric history: be alert for hallucinations or confusion. - Avoid use in patients with known hypersensitivity to any component. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lecigon can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline, rasagiline): risk of hypertensive crisis. - Non‑selective MAO inhibitors (e.g., phenelzine): may cause severe hypertension.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - Antidiabetic drugs: possible masking of hypoglycemia symptoms. - Iron or calcium supplements: may reduce levodopa absorption if taken simultaneously. - Antipsychotics: can diminish levodopa’s therapeutic response.